The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Open accessAbstract
Propagation of venous thrombi or rethrombosis after coronary thrombolytic therapy can occur despite heparin administration. To explore potential mechanisms, we set out to determine whether clot-bound thrombin is relatively protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. Using plasma fibrinopeptide A (FPA) levels as an index of thrombin activity, we compared the ability of thrombin inhibitors to block FPA release mediated by fluid-phase thrombin with their activity against the clot-bound enzyme. Incubation of thrombin with citrated plasma results in concentration-dependent FPA generation, which reaches a plateau within minutes. In contrast, there is progressive FPA generation when fibrin clots are incubated with citrated plasma. Heparin, hirudin, hirudin dodecapeptide (hirugen), and D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK) produce concentration-dependent inhibition of FPA release mediated by fluid-phase thrombin. However, heparin is much less effective at inhibiting thrombin bound to fibrin because a 20-fold higher concentration is necessary to block 70% of the activity of the clot-bound enzyme than is required for equivalent inhibition of fluid-phase thrombin (2.0 and 0.1 U/ml, respectively). In contrast, hirugen and PPACK are equally effective inhibitors of fluid- and solid-phase thrombin, while hirudin is only 50% as effective against the clot-bound enzyme. None of the inhibitors displace bound 125I-labeled thrombin from the clot. These studies indicate that (a) clot-bound thrombin is relatively protected from inhibition by heparin, possibly because the heparin binding site on thrombin is inaccessible when the enzyme is bound to fibrin, and (b) clot-bound thrombin is susceptible to inactivation by antithrombin III-independent inhibitors because the sites of their interaction are not masked by thrombin binding to fibrin. For these reasons, antithrombin III-independent inhibitors may be more effective than heparin in certain clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor
Rosenberg, R. D., & Damus, P. S. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43472-8 · Cited by 1,356
Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Self-citationWarfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis
Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D., McLoughlin, D., & Armstrong, P. (1979) · New England Journal of Medicine · doi:10.1056/nejm197910183011602 · Cited by 604
Self-citationKinetics of the inhibition of thrombin by hirudin
Stone, S. R., & Hofsteenge, J. (1986) · Biochemistry · doi:10.1021/bi00364a025 · Cited by 586
NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS
LAGERSTEDT, C. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90459-3 · Cited by 569
Measurement of Fibrinopeptide A in Human Blood
Nossel, H. L., Yudelman, I., Canfield, R. E., Butler, V. P., Spanondis, K., Wilner, G. D., & Qureshi, G. D. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107749 · Cited by 531
Mechanism of the anticoagulant action of heparin
Bj�rk, I., & Lindahl, U. (1982) · Molecular and Cellular Biochemistry · doi:10.1007/bf00421226 · Cited by 494
A two-step fibrinogen–fibrin transition in blood coagulation
Blombäck, B., Hessel, B., Hogg, D., & Therkildsen, L. (1978) · Nature · doi:10.1038/275501a0 · Cited by 476
Hogg, P. J., & Jackson, C. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3619 · Cited by 347
D-PHE-PRO-ARGCH2Cl-A selective affinity label for thrombin
Kettner, C., & Shaw, E. (1979) · Thrombosis Research · doi:10.1016/0049-3848(79)90014-8 · Cited by 323
Heparin kinetics in venous thrombosis and pulmonary embolism.
Hirsh, J., van Aken, W. G., Gallus, A. S., Dollery, C. T., Cade, J. F., & Yung, W. L. (1976) · Circulation · doi:10.1161/01.cir.53.4.691 · Cited by 277
Self-citationTopol, E. J., George, B. S., Kereiakes, D. J., Stump, D. C., Candela, R. J., Abbottsmith, C. W., Aronson, L., Pickel, A., Boswick, J. M., & Lee, K. L. (1989) · Circulation · doi:10.1161/01.cir.79.2.281 · Cited by 275
Marder, V. J., Soulen, R. L., Atichartakarn, V., Budzynski, A. Z., Parulekar, S. G., Kim, J. R., Edward, N., Zahavi, J., & Algazy, K. M. (1977) · PubMed · Cited by 266
Danielsson, A., Raub, E., Lindahl, U., & Björk, I. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66735-3 · Cited by 252
The binding of thrombin by fibrin.
Liu, C. Y., Nossel, H. L., & Kaplan, K. L. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)86724-8 · Cited by 219
Note on the Adsorption of Thrombin on Fibrin
Seegers, W. H., Nieft, M., & Loomis, E. C. (1945) · Science · doi:10.1126/science.101.2629.520 · Cited by 119
Transient Kinetics of Heparin-catalyzed Protease Inactivation by Antithrombin III
Craig, P., Olson, S. T., & Shore, J. D. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83566-9 · Cited by 100
Localization of the binding site on fibrin for the secondary binding site of thrombin
Váli, Z., & Scheraga, H. A. (1988) · Biochemistry · doi:10.1021/bi00406a023 · Cited by 66
Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
Olcott, C. (1986) · Journal of Vascular Surgery · doi:10.1016/0741-5214(86)90213-2 · Cited by 58
Cited by
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260406 · Cited by 2,717
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Self-citation
Metadata
- Authors
- Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., & Hirsh, J.
- Venue
- Journal of Clinical Investigation
- Published
- 1990-08-01
- Volume
- 86
- Issue
- 2
- Pages
- 385-391
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2138849164
- Cited by
- 1,123
- References
- 19
- FWCI
- 28.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.